Novartis: Depressive Disorder, Major trials
The registry lists 11 Depressive Disorder, Major studies with Novartis as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 1Phase 2 3Phase 3 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)CompletedNCT05454410Phase 2Results posted
- Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With IntentTerminatedNCT04722666Phase 2Results posted
- Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant DepressionCompletedNCT03756129Phase 2Results posted
- An Open-label, Adaptive Design, Positron Emission Tomography Study in Healthy Male Participants to Characterize Receptor Occupancy by MIJ821 in the BrainCompletedNCT05666687Phase 1
- Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)TerminatedNCT01156415Phase 3
- Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)CompletedNCT01110902Phase 3
- Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive DisorderCompletedNCT01110889Phase 3
- Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive DisorderCompletedNCT00467402Phase 3
- A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)CompletedNCT00463242Phase 3
- Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderCompletedNCT00411242Phase 3
- Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive DisorderCompletedNCT00411099Phase 3